Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] slipped around -97.29 points on Tuesday, while shares priced at $374.98 at the close of the session, down -20.60%.
Compared to the average trading volume of 1.53M shares, VRTX reached a trading volume of 10718486 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vertex Pharmaceuticals, Inc [VRTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRTX shares is $491.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRTX stock is a recommendation set at 2.03. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Vertex Pharmaceuticals, Inc shares, keeping their opinion on the stock as Peer Perform, with their previous recommendation back on May 07, 2025. The new note on the price target was released on May 06, 2025, representing the official price target for Vertex Pharmaceuticals, Inc stock. Previously, the target price had yet another raise to $535, while Cantor Fitzgerald analysts kept a Overweight rating on VRTX stock. On February 12, 2025, analysts increased their price target for VRTX shares from 408 to 424.
The Price to Book ratio for the last quarter was 5.60, with the Price to Cash per share for the same quarter was set at 24.86.
How has VRTX stock performed recently?
Vertex Pharmaceuticals, Inc [VRTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.95. With this latest performance, VRTX shares dropped by -18.38% in over the last four-week period, additionally sinking by -20.28% over the last 6 months – not to mention a drop of -6.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRTX stock in for the last two-week period is set at 25.02, with the RSI for the last a single of trading hit 19.78, and the three-weeks RSI is set at 14.36 for Vertex Pharmaceuticals, Inc [VRTX]. The present Moving Average for the last 50 days of trading for this stock 454.58, while it was recorded at 447.08 for the last single week of trading, and 463.09 for the last 200 days.
Vertex Pharmaceuticals, Inc [VRTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vertex Pharmaceuticals, Inc [VRTX] shares currently have an operating margin of 38.24% and a Gross Margin at 87.39%. Vertex Pharmaceuticals, Inc’s Net Margin is presently recorded at 31.98%.
Vertex Pharmaceuticals, Inc (VRTX) Capital Structure & Debt Analysis
According to recent financial data for Vertex Pharmaceuticals, Inc. ( VRTX), the Return on Equity (ROE) stands at 22.77%, reflecting robust shareholder value creation. The Return on Assets (ROA) is 16.47%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Vertex Pharmaceuticals, Inc’s Return on Invested Capital (ROIC) is 19.45%, showcasing its effectiveness in deploying capital for earnings.
Vertex Pharmaceuticals, Inc (VRTX) Efficiency & Liquidity Metrics
Based on Vertex Pharmaceuticals, Inc’s (VRTX) latest financial statements, the Debt-to-Equity Ratio is 0.09%, indicating its reliance on debt financing relative to shareholder equity.
Vertex Pharmaceuticals, Inc (VRTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Vertex Pharmaceuticals, Inc. (VRTX) effectively leverages its workforce, generating an average of $596721.31 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.52% and a Quick Ratio of 2.16%, indicating strong ability to cover short-term liabilities.
Insider trade positions for Vertex Pharmaceuticals, Inc [VRTX]
There are presently around $98.14%, or 98.28% of VRTX stock, in the hands of institutional investors. The top three institutional holders of VRTX stocks are: CAPITAL WORLD INVESTORS with ownership of 26.71 million shares, which is approximately 10.3479%. VANGUARD GROUP INC, holding 22.98 million shares of the stock with an approximate value of $$10.77 billion in VRTX stocks shares; and VANGUARD GROUP INC, currently with $$9.99 billion in VRTX stock with ownership which is approximately 8.2574%.
